



M. Mirshahi M. D., Ph. D, Dr. Sc.  
Université de Paris  
CAP Parti Teck, , INSERM U1275  
Carcinose, Angiogenèse et Recherche Translationnelle  
Hôpital Lariboisière  
2 rue Ambroise Paré  
75010, Paris, France  
Tel: 00 33 1 53216775  
Fax: 00 33 1 53216739  
mail: [massoud.mirshahi@inserm.fr](mailto:massoud.mirshahi@inserm.fr)

**Massoud MIRSHAHI:** M. D., Ph.D, French nationality, Researcher in CNRS (1986- p), Professor of oncology (2009-p), Academician (Tajikistan Academy of Sciences, 2002, FM), Co-head of Regenerative Medicine in Avicenna University, Dushanbe (Tajikistan 2009-2015), 6 patents and several licenses for industrial exploitation, several scientist awards such as Immunopathology of the Eye, Tokyo Japan, 1986, American College of Toxicology » 2002, Pennsylvania, USA, Prize of “Institut de France” (Prix Dalloz), 2006, Paris, over 200 international scientific publications, 270 congress communications. Reviewer in several International Journals such as in Oncology, immunology and Ophthalmology. Member of several International Academic Associations, Thesis director of more than 20 postgraduate students and several master, and postdoctoral students. Obtaining of research grants from several local associations, French or foreign industries and foundations. Main research specialty is: cancerology, thrombosis and coagulation, ocular immunopathology, principal activity: role of the microenvironment in cancer cell proliferation, metastasis and resistance to therapy. Discovery of a tumour micro-environmental cell (named Hospicell) protecting cancer cells from chemotherapy by different mechanisms. Stem cell therapy for heart regenerative medicine and target therapy in cancer disease.

**Key words:** Arrestin, Plasminogen activators, Fibrin-Fibrinogen, Thrombosis, D-Dimer, Autoimmune-disease, Mineralocorticoid receptor (MCR), epithelial sodium channel (eNaC), ophthalmology (Retina and cornea), Cancer, Angiogenesis, Chemoresistance, leukemia, Bone marrow stromal cells, Hospicell, Biomaterial, Nanoparticle, Radio-frequency Plasma, mesenchymal cells, stem cells, regenerative medicine, carcinomatosis. Personalized medicine.